Research programme: fibroblast growth factor-2 binding peptides - sigma-tau
Latest Information Update: 29 Sep 2010
At a glance
- Originator sigma-tau SpA
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 08 Jan 2008 Preclinical trials in Immunological disorders in Italy (unspecified route)